GISONDI, Paolo
 Distribuzione geografica
Continente #
NA - Nord America 8.936
EU - Europa 7.991
AS - Asia 6.276
SA - Sud America 1.033
AF - Africa 193
OC - Oceania 66
Continente sconosciuto - Info sul continente non disponibili 5
AN - Antartide 1
Totale 24.501
Nazione #
US - Stati Uniti d'America 8.796
SG - Singapore 2.815
GB - Regno Unito 1.880
IT - Italia 1.832
CN - Cina 1.677
BR - Brasile 902
HK - Hong Kong 850
RU - Federazione Russa 793
IE - Irlanda 643
FR - Francia 611
DE - Germania 602
SE - Svezia 558
FI - Finlandia 463
KR - Corea 216
VN - Vietnam 143
UA - Ucraina 126
NL - Olanda 109
TR - Turchia 104
ES - Italia 95
ID - Indonesia 90
IN - India 86
TG - Togo 72
CA - Canada 70
JP - Giappone 57
AU - Australia 55
AT - Austria 52
PL - Polonia 46
MX - Messico 44
AR - Argentina 40
ZA - Sudafrica 36
BD - Bangladesh 31
BE - Belgio 29
CH - Svizzera 27
IR - Iran 27
EC - Ecuador 23
SA - Arabia Saudita 22
UZ - Uzbekistan 20
CL - Cile 18
EG - Egitto 17
MA - Marocco 17
MY - Malesia 15
CZ - Repubblica Ceca 14
CO - Colombia 13
PK - Pakistan 13
DK - Danimarca 12
KE - Kenya 12
PT - Portogallo 11
RO - Romania 11
TN - Tunisia 11
BO - Bolivia 10
DZ - Algeria 10
IQ - Iraq 10
NZ - Nuova Zelanda 10
PH - Filippine 10
GR - Grecia 9
HU - Ungheria 9
IL - Israele 9
LT - Lituania 9
PY - Paraguay 9
KZ - Kazakistan 8
TH - Thailandia 7
TW - Taiwan 7
VE - Venezuela 7
AL - Albania 6
HR - Croazia 6
IS - Islanda 6
JO - Giordania 6
MM - Myanmar 6
UY - Uruguay 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
EE - Estonia 5
GE - Georgia 5
JM - Giamaica 5
BG - Bulgaria 4
BN - Brunei Darussalam 4
BY - Bielorussia 4
ET - Etiopia 4
GH - Ghana 4
LK - Sri Lanka 4
NO - Norvegia 4
NP - Nepal 4
OM - Oman 4
AM - Armenia 3
EU - Europa 3
HN - Honduras 3
LV - Lettonia 3
PE - Perù 3
AO - Angola 2
BH - Bahrain 2
CI - Costa d'Avorio 2
GD - Grenada 2
KW - Kuwait 2
LB - Libano 2
LU - Lussemburgo 2
MN - Mongolia 2
PA - Panama 2
PR - Porto Rico 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
Totale 24.466
Città #
Southend 1.591
Dallas 1.435
Singapore 1.251
Chandler 1.055
Jacksonville 954
Hong Kong 834
Dublin 632
Woodbridge 552
Ashburn 536
Ann Arbor 431
Houston 429
Beijing 279
Wilmington 220
Lawrence 215
Princeton 215
New York 151
Milan 146
Helsinki 142
Munich 142
Jinan 135
Verona 134
Nanjing 132
Rome 115
Los Angeles 103
Shenyang 100
The Dalles 99
Sindelfingen 93
Jakarta 75
Lomé 72
São Paulo 65
Hebei 63
Santa Clara 62
Haikou 55
Seattle 54
Ho Chi Minh City 53
Buffalo 51
Changsha 51
Guangzhou 51
Tianjin 50
Chicago 48
Moscow 48
Washington 48
Columbus 46
Hangzhou 44
Nanchang 44
Redwood City 42
Bologna 41
Council Bluffs 40
Madrid 40
Naples 38
Lappeenranta 37
Redondo Beach 35
Zhengzhou 35
Amsterdam 34
Boardman 34
London 34
Jiaxing 33
Rio de Janeiro 32
Warsaw 32
Brooklyn 30
Frankfurt am Main 30
Nuremberg 30
Vienna 30
Falls Church 29
Hanoi 29
Kent 29
Tokyo 29
Turin 29
Belo Horizonte 28
Ningbo 28
Brussels 27
Redmond 27
Esslingen am Neckar 25
Toronto 24
Venice 24
Atlanta 23
Taizhou 23
Fairfield 22
San Francisco 22
Genoa 21
Norwalk 21
Phoenix 21
Seoul 21
Shanghai 21
Florence 20
Johannesburg 20
Stockholm 20
Parma 19
Sydney 19
Brasília 18
Düsseldorf 18
Vicenza 18
Brescia 17
Campinas 17
Curitiba 17
Lancaster 17
Tashkent 17
Dongguan 16
Mexico City 16
Chennai 15
Totale 14.535
Nome #
Pemfigoide cicatriziale di Brunsting-Perry: descrizione di un caso. 629
Interstitial granulomatous dermatitis: a distinct entity withcharacteristic histological and clinical pattern 389
La “Cross Unit”, una nuova modalità per ottimizzare il trattamento topico della psoriasi 330
Il ruolo della vitamina D nella dermatite atopica 259
Dietary supplements for lipedema 256
A new instrument for the screening of psoriatic arthritis among psoriatic patients 254
Real-World Effectiveness of Bimekizumab in Predominantly Difficult-to-Treat Patients with Psoriatic Arthritis Followed in a Combined Dermatology-Rheumatology Clinic: A 24-Week Multicenter Study 244
A systematic review of treatments for pityriasis lichenoides 241
A itchy vesiculobullous eruption in a patient with chronic lymphocytic leukemia. 155
Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis 145
Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. 135
Polymorphisms, diet and nutrigenomics 130
Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy 129
H1 histamine receptor mediates inflammatory responses in human keratinocytes. 127
State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. 126
Squamous cell carcinoma arising in lupus vulgaris. 125
The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis 124
Advanced Glycation End Products in the Pathogenesis of Psoriasis 123
Vitamin D levels in patients with psoriasis with or without arthritis 122
Tossicodermia indotta da oxcarbamazepina: descrizione di un caso. 122
Impact of TNF-α antagonists on the quality of life in selected skin diseases 119
Retention rate of systemic drugs in patients with chronic plaque psoriasis 118
Nonalcoholic fatty liver disease in patients with chronic plaque psoriasis. 118
Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial 117
Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. 117
Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis 116
Steatosi epatica non alcolica in pazienti con psoriasi cronica in placche. 115
Heat urticaria: a revision of published cases with an update on classification and management 115
Severe impairment of quality of life in Hailey-Hailey disease. 114
Balneotherapy for chronic plaque psoariasis at Comano spa in Trentino, Italy. 113
Lower limbs enthesopathy in psoriasic patients without clinical signs of arthropathy: a bospital based case-control study. 111
Incidence of respiratory and allergic symptoms in Italian and immigrant children 111
Lebbra lepromatosa. 110
Acneiform eruption induced by cetuximab 110
C-reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis 110
Annular Lichenoid Dermatitis of Youth: Report of Six New Cases with Review of the Literature 108
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis 108
Psoriasis and the metabolic syndrome 108
Impact of the COVID-19 pandemic on melanoma diagnosis 108
Survival rate of antitumour necrosis factor-a treatments for psoriasis in routine dermatological practice: a multicentre observational study 108
Psoriasis, the liver, and the gastrointestinal tract 107
The expectations of patients with psoriasis during an office consultation 107
A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis. 106
Prevalence of symptoms experienced by patients with different clinical types of psoriasis. 105
The efficacy and safety of topical pimecrolimus in pediatric patients with atopic dermatitis. 105
Effective management of psoriasis symptom worsening durino efalizumab therapy without discontinuing treatment: A case study. 105
Weight reduction alone may not be sufficient to maintain disease remission in obese patients with psoriasis: a randomized, investigator-blinded study. 105
Psoriasi. Una guida per una migliore gestione del paziente. 104
Attitude to treatment of patients with psoriasis attending SPA center 104
Balneotherapy for atopic dermatitis in children at Comano spa in Trentino, Italy 103
Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. 102
Targeting TNF-a in psoriasis and psoriatic arthritis. 102
Pimecrolimus in dermatology: atopic dermatitis and beyond. 101
The metabolic syndrome in psoriasis 101
TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis 101
Erythema nodosum: etiological factors and relapses in a retrospective cohort study. 100
The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development. 100
Image Gallery: Pyoderma gangrenosum of the penis. 100
Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. 99
Dermatite atopica. 98
Complicanze dell'obesità: la cute 98
Targeting tumor necrosis factor a in the therapy of psoriasis. 98
Gender perspective in the management of psoriasis 98
Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy 97
Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis 97
The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis 97
Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. 96
Aggiornamento sulla terapie biologiche della psoriasi 95
Hyperuricaemia in patients with chronic plaque psoriasis. 95
Metabolic comorbidities and psoriasis. 94
L’organo pelle: struttura, biologia, funzioni. 94
Effects of secukinumab on serum adipocytokines: preliminary data 94
The diagnostic and therapeutic challenge of early psoriatic arthritis 94
Preliminary evidence that subclinical enthesopathy may predict psoriatic arthritis in patients with psoriasis 94
The importance of treating mild atopic dermatitis. 93
Patients with psoriasis have a higher prevalence of parental cardiovascular disease 93
Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study 93
Systemic therapy of psoriasis in diabetic patients 93
Perception of disease and doctor-patient relationship experienced by patients with psoriasis. A questionnaire-based study 93
Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review 92
Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid 92
Imiquimod: un ruolo nel trattamento topico della epidermodisplasia verruciforme? 91
Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. 91
PSORIASIS 91
New insights into the autoantibody-mediated mechanisms of autoimmune bullous diseases and urticaria. 90
Chronic plaque psoriasis is associated with increased arterial stiffness 90
Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare 90
Microcircolatory modifications of psoriatic lesions during topical therapy. 89
Cardiometabolic comorbidities: the fingerprint of psoriasis 89
Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. 89
Diabetes and the Skin 88
Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer 88
Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products 88
Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. 87
A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis 87
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study 87
The need for long-term continuous therapy in moderate to severe chronic plaque psoriasis 86
La dermatite atopica nella seconda infanzia ed adolescenza 86
Some considerations about the importance of alliance between patients and dermatologists in psoriasis 86
Usefulness of the Framingham risk score in patients with chronic psoriasis 85
Totale 12.142
Categoria #
all - tutte 101.198
article - articoli 98.007
book - libri 346
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.845
Totale 202.396


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.146 0 0 66 168 199 198 42 100 100 27 184 62
2021/20221.439 86 230 38 121 88 91 54 109 79 55 125 363
2022/20233.858 269 238 357 605 270 889 66 195 503 213 181 72
2023/20242.533 119 197 240 281 261 403 149 157 35 110 342 239
2024/20256.581 386 349 230 1.037 360 299 414 308 941 466 582 1.209
2025/20263.842 1.418 925 1.499 0 0 0 0 0 0 0 0 0
Totale 24.897